Anaptysbio Inc (ANAB)

Mar 24, 2025, 9:15 AM EDT - 9 days ago

Anaptys Announces Stock Repurchase Plan

Feb 27, 2025, 4:15 PM EST - 4 weeks ago

Anaptys Announces Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update

Feb 27, 2025, 4:15 PM EST - 4 weeks ago

Anaptys Announces Participation in March Investor Conferences

Feb 12, 2025, 7:30 AM EST - 7 weeks ago

Anaptys Announces Rosnilimab Achieved Positive Results in RA Phase 2b Trial and Highest Ever Reported CDAI LDA Response Over 6 Months

Feb 11, 2025, 5:30 PM EST - 7 weeks ago

Anaptys to Announce Top-line Data from Phase 2b Trial of Rosnilimab, a PD-1 Depleter and Agonist, in Rheumatoid Arthritis on Feb. 12, 2025

Feb 3, 2025, 4:15 PM EST - 2 months ago

Anaptys to Present at the Guggenheim SMID Cap Biotech Conference

Feb 3, 2025, 7:30 AM EST - 2 months ago

Vanda Pharmaceuticals and Anaptys Announce Exclusive Global License Agreement for Vanda to Develop and Commercialize Imsidolimab, an IL-36R Antagonist

Jan 7, 2025, 9:15 AM EST - 3 months ago

Anaptys to Present at the 43rd Annual J.P. Morgan Healthcare Conference

Dec 11, 2024, 2:07 PM EST - 4 months ago

AnaptysBio Discontinues Investment In Eczema Candidate After Disappointing Data

Dec 11, 2024, 10:20 AM EST - 4 months ago

AnaptysBio to abandon eczema drug development after mid-stage trial failure

Dec 11, 2024, 8:42 AM EST - 4 months ago

AnaptysBio abandons eczema drug development after mid-stage trial failure

Dec 11, 2024, 8:30 AM EST - 4 months ago

Anaptys Announces Phase 2b Trial of ANB032, a BTLA Agonist, Did Not Meet Primary or Secondary Endpoints in Atopic Dermatitis

Nov 5, 2024, 4:15 PM EST - 5 months ago

Anaptys Announces Participation in November and December Investor Conferences

Nov 5, 2024, 4:15 PM EST - 5 months ago

Anaptys Announces Third Quarter 2024 Financial Results and Provides Business Update

Aug 29, 2024, 9:15 AM EDT - 7 months ago

Anaptys Announces Participation in September Investor Conferences

Aug 15, 2024, 2:14 PM EDT - 8 months ago

AnaptysBio: Top-Line AD Data End Of 2024 Could Be Turning Point

Aug 14, 2024, 5:00 AM EDT - 8 months ago

Anaptys Announces Pricing of $100 Million Underwritten Registered Direct Offering

Aug 5, 2024, 4:15 PM EDT - 8 months ago

Anaptys Announces Second Quarter 2024 Financial Results and Provides Business Update

Jul 22, 2024, 2:53 PM EDT - 9 months ago

AnaptysBio Investigational Arthritis Drug Might Have Better Efficacy Profile Than Eli Lilly's: Analyst

May 9, 2024, 4:15 PM EDT - 11 months ago

Anaptys Announces First Quarter 2024 Financial Results and Provides Business Update

May 9, 2024, 4:10 PM EDT - 11 months ago

Anaptys Announces Positive Top-Line GEMINI-2 Phase 3 Clinical Trial Results of Imsidolimab (IL-36R) in Generalized Pustular Psoriasis (GPP)

May 9, 2024, 4:05 PM EDT - 11 months ago

Anaptys to Receive $50 Million in a Capped Non-Recourse Monetization from Amended Agreement with Sagard in Exchange for Additional Jemperli Royalties

Apr 24, 2024, 9:00 AM EDT - 1 year ago

Actym Therapeutics Appoints Thomas Smart as CEO

PGEN XOMA

Mar 11, 2024, 4:15 PM EDT - 1 year ago

Anaptys Announces Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update

Feb 29, 2024, 9:15 AM EST - 1 year ago

Anaptys to Present at TD Cowen's 44th Annual Health Care Conference and 2024 AAD Annual Meeting

Jan 31, 2024, 9:15 AM EST - 1 year ago

Anaptys to Present at Guggenheim's 6th Annual Biotechnology Conference

Nov 27, 2023, 4:15 PM EST - 1 year ago

Anaptys Expands Immune Cell Modulator Pipeline with Exclusive License to BDCA2 Modulator Antibody Portfolio from Centessa Pharmaceuticals

Nov 7, 2023, 4:15 PM EST - 1 year ago

Anaptys Named a BioSpace 2024 Best Places to Work Winner

Nov 2, 2023, 4:15 PM EDT - 1 year ago

Anaptys Announces Third Quarter 2023 Financial Results and Provides Business Update

Nov 1, 2023, 9:15 AM EDT - 1 year ago

Anaptys Announces Participation in November Investor Conferences

Oct 11, 2023, 9:15 AM EDT - 1 year ago

Anaptys to Present Phase 1 Data on ANB032, its BTLA Agonist Antibody, at the 32nd EADV Congress

Oct 9, 2023, 8:32 AM EDT - 1 year ago

AnaptysBio's skin disease drug meets main goal in late-stage study

Oct 9, 2023, 8:15 AM EDT - 1 year ago

Anaptys to Provide Overview of Rosnilimab, a PD-1 Agonist, at Virtual R&D Event on Wednesday, Oct. 25

Oct 9, 2023, 8:00 AM EDT - 1 year ago

Anaptys Announces Positive Top-Line Phase 3 Clinical Trial Results of Imsidolimab (IL-36R) in Generalized Pustular Psoriasis (GPP)

Sep 18, 2023, 4:15 PM EDT - 1 year ago

AnaptysBio Announces Appointment of John Orwin as Chairman of the Board of Directors

Sep 12, 2023, 9:15 AM EDT - 1 year ago

AnaptysBio to Present at the Stifel 2023 Immunology and Inflammation Virtual Summit

Aug 7, 2023, 4:15 PM EDT - 1 year ago

AnaptysBio Announces Second Quarter 2023 Financial Results and Provides Business Update

Jul 31, 2023, 1:34 PM EDT - 1 year ago

AnaptysBio- and GSK-Partnered Immuno-Oncology Agent JEMPERLI (dostarlimab-gxly) plus Chemotherapy Approved in the U.S. for dMMR/MSI-H Primary Advanced or Recurrent Endometrial Cancer

Jul 7, 2023, 10:33 AM EDT - 1 year ago

AnaptysBio: Despite Early Successes, Current Situation Does Not Impress

May 30, 2023, 4:15 PM EDT - 2 years ago

AnaptysBio Announces Participation in Upcoming Investor Conferences

May 11, 2023, 4:15 PM EDT - 2 years ago

AnaptysBio Announces First Quarter 2023 Financial Results and Provides Pipeline Update

May 2, 2023, 9:15 AM EDT - 2 years ago

AnaptysBio Announces British Journal of Dermatology Publication of Imsidolimab (IL-36R) Previously Reported Phase 2 GALLOP Data in Generalized Pustular Psoriasis (GPP)

Apr 6, 2023, 4:15 PM EDT - 2 years ago

AnaptysBio Announces Appointment of Rita Jain, M.D., to Board of Directors

Mar 30, 2023, 11:44 PM EDT - 2 years ago

AnaptysBio: Upside Could Be Lying Ahead Very Nicely

Mar 27, 2023, 6:50 PM EDT - 2 years ago

AnaptysBio- and GSK-partnered immuno-oncology agent Jemperli (dostarlimab-gxly) plus chemotherapy demonstrates statistically significant and clinically meaningful improvement in progression-free survival for the treatment of primary advanced or recurrent

Mar 1, 2023, 4:05 PM EST - 2 years ago

AnaptysBio Announces Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update

Feb 27, 2023, 4:05 PM EST - 2 years ago

AnaptysBio to Participate at the Cowen and Company 43rd Annual Health Care Conference

Jan 13, 2023, 9:00 AM EST - 2 years ago

AnaptysBio Announces Stock Repurchase Plan

Jan 5, 2023, 4:05 PM EST - 2 years ago

AnaptysBio Announces Portfolio Update Across Best-in-Class Immune Cell Modulating Antibodies

Dec 2, 2022, 9:00 AM EST - 2 years ago

AnaptysBio- and GSK-partnered immuno-oncology agent JEMPERLI (dostarlimab-gxly) meets primary endpoint in Phase 3 RUBY trial in primary advanced or recurrent endometrial cancer